IL1RL1 and cancer: Kudo-Saito, C et al. reported that soluble IL-33 released from cancer cells stimulates the expression of ST-2 on IL17 Receptor B positive (IL17RB+) and GATA Binding Protein 3 positive (GATA3+) cells, thus leading to tumor progression [63].